ATE450619T1 - Defructosylierungsverfahren - Google Patents

Defructosylierungsverfahren

Info

Publication number
ATE450619T1
ATE450619T1 AT03758816T AT03758816T ATE450619T1 AT E450619 T1 ATE450619 T1 AT E450619T1 AT 03758816 T AT03758816 T AT 03758816T AT 03758816 T AT03758816 T AT 03758816T AT E450619 T1 ATE450619 T1 AT E450619T1
Authority
AT
Austria
Prior art keywords
defructosylation
protein
enzyme
fructosylated peptide
fructosylated
Prior art date
Application number
AT03758816T
Other languages
English (en)
Inventor
Hiroyuki Ebinuma
Original Assignee
Daiichi Pure Chemicals Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daiichi Pure Chemicals Co Ltd filed Critical Daiichi Pure Chemicals Co Ltd
Application granted granted Critical
Publication of ATE450619T1 publication Critical patent/ATE450619T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/795—Porphyrin- or corrin-ring-containing peptides
    • C07K14/805—Haemoglobins; Myoglobins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0012—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7)
    • C12N9/0014—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on the CH-NH2 group of donors (1.4)
    • C12N9/0022—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on the CH-NH2 group of donors (1.4) with oxygen as acceptor (1.4.3)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/005—Glycopeptides, glycoproteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/26—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving oxidoreductase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/72—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood pigments, e.g. haemoglobin, bilirubin or other porphyrins; involving occult blood
    • G01N33/721—Haemoglobin
    • G01N33/725—Haemoglobin using peroxidative activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2400/00—Assays, e.g. immunoassays or enzyme assays, involving carbohydrates

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Urology & Nephrology (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Metal-Oxide And Bipolar Metal-Oxide Semiconductor Integrated Circuits (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
AT03758816T 2002-10-23 2003-10-23 Defructosylierungsverfahren ATE450619T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2002308731 2002-10-23
PCT/JP2003/013547 WO2004038033A1 (ja) 2002-10-23 2003-10-23 脱フルクトシル化方法

Publications (1)

Publication Number Publication Date
ATE450619T1 true ATE450619T1 (de) 2009-12-15

Family

ID=32170987

Family Applications (2)

Application Number Title Priority Date Filing Date
AT03758817T ATE423216T1 (de) 2002-10-23 2003-10-23 Neue fructosylpeptidoxidase und deren nutzung
AT03758816T ATE450619T1 (de) 2002-10-23 2003-10-23 Defructosylierungsverfahren

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT03758817T ATE423216T1 (de) 2002-10-23 2003-10-23 Neue fructosylpeptidoxidase und deren nutzung

Country Status (7)

Country Link
US (2) US7393549B2 (de)
EP (2) EP1555324B1 (de)
JP (2) JP4323429B2 (de)
AT (2) ATE423216T1 (de)
AU (2) AU2003275612A1 (de)
DE (2) DE60330376D1 (de)
WO (2) WO2004038033A1 (de)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR059898A1 (es) 2006-03-15 2008-05-07 Janssen Pharmaceutica Nv Derivados de 3-ciano-piridona 1,4-disustituida y su uso como moduladores alostericos de los receptores mglur2
TW200900065A (en) 2007-03-07 2009-01-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives
TW200845978A (en) 2007-03-07 2008-12-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives
EA017648B1 (ru) 2007-09-14 2013-02-28 Орто-Макнейл-Янссен Фармасьютикалз, Инк. 1',3'-двузамещенные-4-фенил-3,4,5,6-тетрагидро-2н,1'н-[1,4']бипириди-нил-2'-оны
BRPI0816970A2 (pt) 2007-09-14 2015-03-24 Ortho Mcneil Janssen Pharm 1,3-dissubstituídas-4-fenil-1h-piridin-2-onas
TW200922566A (en) 2007-09-14 2009-06-01 Ortho Mcneil Janssen Pharm 1,3 disubstituted 4-(aryl-X-phenyl)-1H-pyridin-2-ones
CA2704436C (en) 2007-11-14 2016-01-05 Ortho-Mcneil-Janssen Pharmaceuticals, Inc. Imidazo[1,2-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
JP5547194B2 (ja) 2008-09-02 2014-07-09 ジャンセン ファーマシューティカルズ, インコーポレイテッド. 代謝型グルタミン酸受容体の調節因子としての3−アザビシクロ[3.1.0]ヘキシル誘導体
CA2739881A1 (en) 2008-10-09 2010-04-15 Kyowa Medex Co., Ltd. Novel fructosyl peptide oxidase
WO2010043396A1 (en) 2008-10-16 2010-04-22 Ortho-Mcneil-Janssen Pharmaceuticals, Inc. Indole and benzomorpholine derivatives as modulators of metabotropic glutamate receptors
JP5690277B2 (ja) 2008-11-28 2015-03-25 ジャンセン ファーマシューティカルズ, インコーポレイテッド. 代謝型グルタミン酸受容体の調節因子としてのインドールおよびベンゾオキサジン誘導体
HRP20131122T1 (hr) 2009-05-12 2013-12-20 Janssen Pharmaceuticals, Inc. Derivati 1,2,4-triazolo[4,3-a] piridina i njihova uporaba u lijeäśenju ili prevenciji neuroloških i psihijatrijskih poremeä†aja
MY153913A (en) 2009-05-12 2015-04-15 Janssen Pharmaceuticals Inc 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
CN102439015B (zh) 2009-05-12 2015-05-13 杨森制药有限公司 1,2,4-三唑并[4,3-a]吡啶衍生物和其作为mGluR2受体的正向变构调节剂的用途
ES2536433T3 (es) 2010-11-08 2015-05-25 Janssen Pharmaceuticals, Inc. Derivados de 1,2,4-triazolo[4,3-a]piridina y su uso como moduladores alostéricos positivos de receptores mGluR2
JP5852664B2 (ja) 2010-11-08 2016-02-03 ジヤンセン・フアーマシユーチカルズ・インコーポレーテツド 1,2,4−トリアゾロ[4,3−a]ピリジン誘導体およびmGluR2受容体のポジティブアロステリックモジュレーターとしてのそれらの使用
EP2661435B1 (de) 2010-11-08 2015-08-19 Janssen Pharmaceuticals, Inc. 1,2,4-triazol[4,3-a]pyridinderivate und ihre verwendung als positive allosterische mglur2-rezeptormodulatoren
JP5858945B2 (ja) 2012-03-15 2016-02-10 アークレイ株式会社 酵素を用いた測定方法
EP2843050B1 (de) 2012-04-27 2019-03-13 Kikkoman Corporation Zur wirkung auf fructosylhexapeptid fähige, modifizierte amadoriase
JO3368B1 (ar) 2013-06-04 2019-03-13 Janssen Pharmaceutica Nv مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2
CN105431545B (zh) 2013-07-09 2021-06-18 日立化成诊断系统株式会社 糖化血红蛋白的测定方法
CN105431533B (zh) 2013-07-09 2019-06-28 协和梅迪克斯株式会社 糖化六肽氧化酶及其用途
JO3367B1 (ar) 2013-09-06 2019-03-13 Janssen Pharmaceutica Nv مركبات 2،1، 4- ثلاثي زولو [3،4-a] بيريدين واستخدامها بصفة منظمات تفارغية موجبة لمستقبلات ميجلور 2
EP3061829B1 (de) * 2013-10-25 2021-09-22 Kikkoman Corporation Hba1c-messverfahren mit auf glykierte peptide wirkender amadoriase
KR102390390B1 (ko) * 2013-10-25 2022-04-25 기꼬만 가부시키가이샤 헤모글로빈 A1c의 측정 방법 및 측정 키트
PL3096790T3 (pl) 2014-01-21 2020-01-31 Janssen Pharmaceutica, N.V. Kombinacje zawierające pozytywne modulatory allosteryczne lub agonistów ortosterycznych metabotropowego receptora glutaminergicznego podtypu 2 i ich zastosowanie
ME03518B (de) 2014-01-21 2020-04-20 Janssen Pharmaceutica Nv Kombinationen mit positiven allosterischen modulatoren von metabotropem glutamatergen rezeptor vom subtyp 2 und deren verwendung
EP3279323B1 (de) 2015-04-03 2023-03-08 Kikkoman Corporation Amadoriase mit verbesserter spezifischer aktivität
US11111517B2 (en) 2016-04-22 2021-09-07 Kikkoman Corporation HbA1c dehydrogenase
CN108342370B (zh) * 2017-01-22 2021-05-28 上海交通大学 一种新型果糖基肽氧化酶及其应用
EP3677681A4 (de) 2017-08-31 2021-07-14 Kikkoman Corporation Glykierte hämoglobinoxidasevariante und messverfahren

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60109509A (ja) * 1983-11-16 1985-06-15 Narisu Keshohin:Kk 美白化粧料
US4976974A (en) * 1988-06-02 1990-12-11 Chateau Yaldara Pty. Ltd. Grape juice concentrate and drink
GB9116315D0 (en) 1991-07-29 1991-09-11 Genzyme Ltd Assay
JP3157622B2 (ja) 1992-06-05 2001-04-16 株式会社ミツカングループ本社 フルクトシルアミンデグリカーゼ、その製造法及び該酵素を用いたアマドリ化合物の定量方法
AU661207B2 (en) * 1992-11-17 1995-07-13 Boehringer Mannheim Gmbh Simultaneous determination of HbA1c and haemoglobin variants with a glycation analogus to HbA1c
JP2923222B2 (ja) 1994-03-03 1999-07-26 株式会社京都第一科学 フルクトシルアミノ酸オキシダーゼ及びその製造方法
JP3850904B2 (ja) 1994-10-05 2006-11-29 アークレイ株式会社 フルクトシルアミノ酸オキシダーゼ及びその製造方法
JP4004081B2 (ja) 1995-04-11 2007-11-07 アークレイ株式会社 フルクトシルアミノ酸オキシダーゼおよびその製造方法
US5741491A (en) * 1995-09-06 1998-04-21 Isotechnika Incorporated Medicinal composition for diabetes
WO1997013872A1 (en) 1995-10-12 1997-04-17 Kyoto Daiichi Kagaku Co., Ltd. Method and assaying amodori compounds
ATE218036T1 (de) * 1996-12-23 2002-06-15 Dsm Nv Verfahren zur herstellung eines proteinhydrolysates
JPH11155579A (ja) 1997-11-25 1999-06-15 Kikkoman Corp フルクトシルアミノ酸オキシダーゼ遺伝子、新規な組み換え体dna及びフルクトシルアミノ酸オキシダーゼの製造法
IN186667B (de) * 1999-01-29 2001-10-20 Ajanta Pharma Ltd
JP2000333696A (ja) 1999-05-26 2000-12-05 Arkray Inc 糖化アミンの測定方法
JP3734212B2 (ja) 1999-08-18 2006-01-11 旭化成ファーマ株式会社 タンパク質の選択的断片化方法
JP4427137B2 (ja) * 1999-08-23 2010-03-03 積水メディカル株式会社 フルクトシルバリンの生産方法
JP3949854B2 (ja) 1999-10-01 2007-07-25 キッコーマン株式会社 糖化蛋白質の測定方法
CN101363044B (zh) * 2000-07-14 2013-01-09 爱科来株式会社 糖基化血红蛋白的选择性测定方法
CN1243831C (zh) 2000-11-28 2006-03-01 龟甲万株式会社 果糖基氨基酸氧化酶
JP4308768B2 (ja) * 2002-09-24 2009-08-05 アークレイ株式会社 フルクトシルアミンオキシダーゼ

Also Published As

Publication number Publication date
EP1555324B1 (de) 2009-12-02
ATE423216T1 (de) 2009-03-15
EP1555324A4 (de) 2006-06-07
JP4323429B2 (ja) 2009-09-02
US7393549B2 (en) 2008-07-01
EP1555325B1 (de) 2009-02-18
JPWO2004038034A1 (ja) 2006-02-23
AU2003275613A1 (en) 2004-05-13
AU2003275612A1 (en) 2004-05-13
JP4327094B2 (ja) 2009-09-09
JPWO2004038033A1 (ja) 2006-02-23
DE60326259D1 (de) 2009-04-02
US20070054344A1 (en) 2007-03-08
WO2004038034A1 (ja) 2004-05-06
DE60330376D1 (de) 2010-01-14
EP1555324A1 (de) 2005-07-20
EP1555325A4 (de) 2006-06-07
EP1555325A1 (de) 2005-07-20
WO2004038033A1 (ja) 2004-05-06
US7329520B2 (en) 2008-02-12
US20060240501A1 (en) 2006-10-26

Similar Documents

Publication Publication Date Title
DE60330376D1 (de) Defructosylierungsverfahren
DK2230299T3 (da) Hidtil ukendt cytokin ZCYTOR17-ligand
CY1105836T1 (el) 12, 13-τροποποιημενα παραγωγα εποθιλονης
EA200300464A1 (ru) ГУМАНИЗИРОВАННОЕ АНТИТЕЛО ПРОТИВ РЕЦЕПТОРА ЛИМФОТОКСИНА-β (ВАРИАНТЫ), КОМПОЗИЦИЯ, СПОСОБ ЛЕЧЕНИЯ ИЛИ СНИЖЕНИЯ РИСКА РАЗВИТИЯ, ТЯЖЕСТИ ИЛИ ПОСЛЕДСТВИЙ НЕОПЛАЗИИ У ЧЕЛОВЕКА, ВЫДЕЛЕННАЯ НУКЛЕИНОВАЯ КИСЛОТА (ВАРИАНТЫ), КЛЕТКА КЛЕТОЧНОЙ ЛИНИИ
EA200400241A1 (ru) Направленные к мишени мультимерные контрастные вещества, основанные на пептидах
BG102577A (bg) Нови 5-амино-3-циано-4-етилсулфинил-1-фенилпиразоли, метод за получаване и използването им като пестициди
DE602004017486D1 (de) Substituierte heteroarylbenzofuransäuren
WO2004019861A3 (en) Stable ph optimized formulation of a modified antibody
HUP0301795A2 (hu) Emberi D-G szerinproteázt kódoló DNS
EA200201138A1 (ru) Пептид, модулирующий рецептор тромбопоэтина
ATE413884T1 (de) Beta-secretase-substrat und seine verwendung
EA199800844A1 (ru) Способ получения r-альфа-пропил-пиперониламина и его аналогов, промежуточные продукты, используемые в этом способе
ATE211719T1 (de) Korrosionsinhibitoren enthaltender injektionszement
DE60332579D1 (de) Prozess zur Immobilisierung von Polypeptiden über die Carboxylgruppe des C-terminus
ATE527280T1 (de) Fluoreszentprotein und chromoprotein
ES2195033T3 (es) Iso-indolonas condensadas utilizadas como inhibidores de proteina quinasa c.
ATE315092T1 (de) Acetylhydrolase des plättchen aktivierenden faktors, und entsprechendes gen
DE50213120D1 (de) Mikrobiologisches verfahren zur herstellung von amiden
DE60334316D1 (de) Frpb proteinmutante und verfahren zur erneuten faltung
ATE379816T1 (de) Architektur zum verarbeiten von fingerabdruckbildern
SE9800865D0 (sv) New Process
DE60131648D1 (de) Die konzentration von wasserdampf kompensierendes kalibrationsverfahren
ATE307201T1 (de) Srcr domäne-enthaltendes protein
DE602004026838D1 (de) Eine metacaspasen-klasse
EP1467207A4 (de) Screening-verfahren

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties